MAP: XTX101 Monotherapy and/or Combination Therapy in Advanced Solid Tumors

MAP: XTX101 Monotherapy and/or Combination Therapy in Advanced Solid Tumors

Es posible que algunos contenidos no estén disponibles en español.

Who Can Participate?

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

A Managed Access Protocol for Patients with Advanced Solid Tumors who have Completed Protocol XTX101-01/02-001 (NCT04896697) Monotherapy Vilastobart (XTX101) and/or Combination Therapy Vilastobart and Atezolizumab and Continue to Receive Benefit from Treatment

Principal Investigator

Nicholas
DeVito

Protocol Number

PRO00120304

Phase

N/A

Enrollment Status

Open to Enrollment